The use of an adjuvant arteriovenous fistula (AVF) in vascular procedures is controversial. The purpose of this study was to evaluate our experience with this adjunct in femorodistal bypass surgery. Patients who received a prosthetic femorocrural bypass with or without an AVF were studied (n = 56). Risk factors, Doppler and plethysmographic characteristics, and preoperative angiograms were analyzed. Of all prosthetic bypasses anastomosed to a single crural vessel, 75% received an AVF (AVF+, n = 44) whereas 25% did not (AVF-, n = 12). Preoperative ankle/brachial pressures and angiographic outflow scores in both groups were comparable. Successful revascularization doubled ankle/brachial pressure indices and tripled toe pressures. Bypasses with a maximum angiographic outflow score performed better than those with low scores (p <0.05). The overall patency rates after 1, 12, and 24 months were 87%, 62%, and 47%, respectively; an AVF did not influence these numbers although a trend favoring the use of a fistula was present at 1 year (AVF-, 54% vs. AVF+, 64%; p = 0.11). Moreover, 2-year limb salvage was not different between groups (AVF-, 75% vs. AVF+, 68%). The use of an AVF in prosthetic femorodistal bypass surgery does not improve rates of patency and limb salvage in the long term.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10016-001-0209-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of the Omniflow II Biosynthetic Graft in Postoperative Wound Problems After Lower Limb Revascularization: A Single Center Prospective Registry.
Ann Vasc Surg
November 2024
Department of Vascular Surgery, University Hospitals Leuven, Leuven, Belgium; Department of Cardiovascular Sciences, Research Unit of Vascular Surgery, KU Leuven, Leuven, Belgium.
Objective: To investigate the role of the Omniflow II prosthesis in the prevention of vascular graft infection (VGI) in patients with peripheral arterial disease and to report on short-and mid-term graft-related morbidity.
Material And Methods: Patients were included in prospective registry between October 2019 and March 2023. The primary endpoint was to report infection-related problems, operation-related wound problems, and short- and mid-term graft-related morbidity.
Antiplatelet and anticoagulation therapy after revascularization for lower extremity artery disease: a national survey and literature overview.
J Cardiovasc Surg (Torino)
February 2021
Department of Vascular Surgery, Northwest Clinics, Alkmaar, the Netherlands.
Background: Antiplatelet therapy (APT) after interventions for lower extremity artery disease (LEAD) is recommended. However, (inter)national guidelines vary on type and duration of APT. This report aimed to present the results of a survey on antithrombotic prescribing patterns after lower limb interventions in the Netherlands and an overview of the available literature on this topic.
View Article and Find Full Text PDFA comparison of femorocrural bypasses performed with modified heparin-bonded expanded polytetrafluorethylene grafts and those with great saphenous vein grafts to treat critical limb ischemia.
Ann Vasc Surg
August 2015
Cardiovascular Diseases Department, Quality and Research Assessment Unit, Infermi Hospital, Rimini, Italy.
Background: The purpose of this study was to evaluate our results involving femorocrural bypasses by comparing heparin-bonded expanded polytetrafluoroethylene (HePTFE) graft (Propaten) modified with handmade distal compliant HePTFE cuffs (mHePTFE graft) to great saphenous vein (GSV) graft.
Methods: A retrospective study involving 74 femorocrural bypasses performed from January 2010 to May 2013 at a single institution was carried out. The indication for revascularization was critical limb ischemia (Rutherford stages 4-6.
Midterm results of autologous saphenous vein and ePTFE pre-cuffed bypass surgery in peripheral arterial occlusive disease.
Vasc Endovascular Surg
October 2011
Department of Surgery, Amphia Hospital, Breda, Netherlands.
Introduction: The graft of choice in lower limb bypass surgery is the autologous saphenous vein (ASV). However, a prosthetic graft is needed in the absence of an ASV. In such situations, we used an expanded polytetrafluoroethylene (ePTFE) pre-cuffed Dynaflo graft as supragenicular bypass or Distaflo graft as infragenicular or femorocrural bypass.
View Article and Find Full Text PDFThe seven-year' secondary patency of a fresh arterial allograft in the femorocrural position in a heart transplant recipient.
Ann Vasc Surg
October 2010
Department of Vascular Surgery, Na Homolce Hospital, Prague, Czech Republic.
Critical limb ischemia in patients with diabetes at the organ complication stage represents a considerable challenge in vascular medicine. Because of the complexity of the disease and the often symmetric involvement of both lower limbs, a discrepancy between suitable vascular conduit availability and the actual requirement can occur: notably, the prevalence of multilevel and diffuse arterial disease often limits the possibilities of endovascular treatment, and, in surgical cases, frequently prohibits the effective use of prosthetic material. In our patient with bilateral critical limb ischemia and previous coronary artery bypass graft followed by cardiac transplantation, only one great saphenous vein remained available.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!